ADAM33 and asthma: We are exploring the delivery of anti-Adam33 oligonucleotides to mouse airways and the therapeutic potential of ASO-mediated inhibition of ADAM33 for reversing pathological airway remodeling in asthma and other chronic lung diseases, including chronic obstructive pulmonary disease (COPD)66, 67 and sarcoidosis.68